Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jan;67(1):119–127. doi: 10.1038/bjc.1993.21

Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study.

T Philip 1, R Ladenstein 1, J M Zucker 1, R Pinkerton 1, E Bouffet 1, D Louis 1, W Siegert 1, J L Bernard 1, D Frappaz 1, C Coze 1, et al.
PMCID: PMC1968211  PMID: 8427772

Abstract

In the LMCE1 study using a single course of megatherapy most of the relapses occurred during the first 2 years after autologous bone marrow transplantation. A second pilot study (LMCE2) was therefore set up using a double harvest/double graft approach with two different megatherapy regimens. Objectives were to test the role of increased dose intensity on response status, relapse pattern and overall survival. Thirty-three patients (20 boys, 13 girls) with a median age of 53 months at first megatherapy (range, 17-202 months) entered this study. They were cases either with refractory disease in partial response after second line treatment for stage 4 neuroblastoma (n = 25) or after relapse from stage 4 (n = 5) or stage 3 disease (n = 3). All patients received Etoposid and/or Cisplatinum (or Carboplatin) containing treatments before megatherapy. The first megatherapy regimen was a combination of Tenoposid, Carmustine and Cisplatinum (or Carboplatin), the second applied Vincristin, Melphalan and Total Body Irradiation. The first harvest was scheduled 4 weeks after the last chemotherapy, the second 60 to 90 days after megatherapy. All marrows were purged in vitro by an immunomagnetic technique. Median follow up time since first megatherapy is 56 months. Response rates for evaluable patients were 65% (complete response rate: 16%) for megatherapy 1 and 60% (complete response rate: 25%) for megatherapy 2. Considering that only patients with delayed response or relapse were eligible for this pilot study the overall survival was encouraging with 36% at 2 years and still 32% at 5 years. The costs for these survival rates were high in terms of morbidity (four early and four late toxic deaths; toxic death rate: 24%). Double harvesting may have the disadvantage of delayed engraftments related in part to a disturbance of marrow microenvironment by megatherapy 1. This double megatherapy approach achieved a prolonged relapse free interval (median 11 months, range 2-31 months) in patients reaching megatherapy 2 and justifies further evaluation of concepts with consecutive dose-escalation.

Full text

PDF
119

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. August C. S., Serota F. T., Koch P. A., Burkey E., Schlesinger H., Elkins W. L., Evans A. E., D'Angio G. J. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol. 1984 Jun;2(6):609–616. doi: 10.1200/JCO.1984.2.6.609. [DOI] [PubMed] [Google Scholar]
  2. Beaujean F., Hartmann O., Benhamou E., Lemerle J., Duedari N. Hemopoietic reconstitution after repeated autologous transplantation with mafosfamide-purged marrow. Bone Marrow Transplant. 1989 Sep;4(5):537–541. [PubMed] [Google Scholar]
  3. Bernard J. L., Philip T., Zucker J. M., Frappaz D., Robert A., Margueritte G., Boilletot A., Philippe N., Lutz P., Roche H. Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen? J Clin Oncol. 1987 Dec;5(12):1952–1959. doi: 10.1200/JCO.1987.5.12.1952. [DOI] [PubMed] [Google Scholar]
  4. Berthold F., Burdach S., Kremens B., Lampert F., Niethammer D., Riehm H., Ritter J., Treuner J., Utsch S., Zieschang J. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience. Klin Padiatr. 1990 Jul-Aug;202(4):262–269. doi: 10.1055/s-2007-1025531. [DOI] [PubMed] [Google Scholar]
  5. Carlsen N. L., Christensen I. J., Schroeder H., Bro P. V., Erichsen G., Hamborg-Pedersen B., Jensen K. B., Nielsen O. H. Prognostic factors in neuroblastomas treated in Denmark from 1943 to 1980. A statistical estimate of prognosis based on 253 cases. Cancer. 1986 Dec 15;58(12):2726–2735. doi: 10.1002/1097-0142(19861215)58:12<2726::aid-cncr2820581229>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  6. Combaret V., Favrot M. C., Kremens B., Philip I., Bailly C., Fontaniere B., Gentilhomme O., Chauvin F., Zucker J. M., Bernard J. L. Immunological detection of neuroblastoma cells in bone marrow harvested for autologous transplantation. Br J Cancer. 1989 Jun;59(6):844–847. doi: 10.1038/bjc.1989.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Favrot M., Philip I., Combaret V., Maritaz O., Philip T. Experimental evaluation of an immunomagnetic bone marrow purging procedure using the Burkitt lymphoma model. Bone Marrow Transplant. 1987 Jun;2(1):59–66. [PubMed] [Google Scholar]
  8. Favrot M., Philip T., Combaret V., Lemerle J., Marie J. P., Bernard A. Effect of in vivo therapy with a CD8 monoclonal antibody on delayed engraftment after autologous bone marrow transplantation. Bone Marrow Transplant. 1990 Jan;5(1):33–38. [PubMed] [Google Scholar]
  9. Graham-Pole J., Gee A., Emerson S., Gallo J., Lee C., Luzins J., Janssen W. E., Pick T., Worthington-White D., Elfenbein G. Myeloablative chemoradiotherapy and autologous bone marrow infusions for treatment of neuroblastoma: factors influencing engraftment. Blood. 1991 Sep 15;78(6):1607–1614. [PubMed] [Google Scholar]
  10. Graham-Pole J., Lazarus H. M., Herzig R. H., Gross S., Coccia P., Weiner R., Strandjord S. High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing's sarcoma. Am J Pediatr Hematol Oncol. 1984 Spring;6(1):17–26. [PubMed] [Google Scholar]
  11. Hartmann O., Benhamou E., Beaujean F., Kalifa C., Lejars O., Patte C., Behard C., Flamant F., Thyss A., Deville A. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol. 1987 Aug;5(8):1205–1211. doi: 10.1200/JCO.1987.5.8.1205. [DOI] [PubMed] [Google Scholar]
  12. Hartmann O., Kalifa C., Benhamou E., Patte C., Flamant F., Jullien C., Beaujean F., Lemerle J. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol. 1986;16(2):165–169. doi: 10.1007/BF00256169. [DOI] [PubMed] [Google Scholar]
  13. Hartmann O., Pinkerton C. R., Philip T., Zucker J. M., Breatnach F. Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma. J Clin Oncol. 1988 Jan;6(1):44–50. doi: 10.1200/JCO.1988.6.1.44. [DOI] [PubMed] [Google Scholar]
  14. Hartmann O., Scopinaro M., Tournade M. F., Sarrazin D., Lemerle J. Neuroblastomes traités à l'Institut Gustave-Roussy de 1975 à 1979. Cent soixante-treize cas. Arch Fr Pediatr. 1983 Jan;40(1):15–21. [PubMed] [Google Scholar]
  15. Kingston J. E., Malpas J. S., Stiller C. A., Pritchard J., McElwain T. J. Autologous bone marrow transplantation contributes to haemopoietic recovery in children with solid tumours treated with high dose melphalan. Br J Haematol. 1984 Dec;58(4):589–595. doi: 10.1111/j.1365-2141.1984.tb06105.x. [DOI] [PubMed] [Google Scholar]
  16. Kushner B. H., Helson L. Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients. J Clin Oncol. 1987 Nov;5(11):1746–1751. doi: 10.1200/JCO.1987.5.11.1746. [DOI] [PubMed] [Google Scholar]
  17. Le Tourneau J. N., Bernard J. L., Hendren W. H., Carcassonne M. Evaluation of the role of surgery in 130 patients with neuroblastoma. J Pediatr Surg. 1985 Jun;20(3):244–249. doi: 10.1016/s0022-3468(85)80113-5. [DOI] [PubMed] [Google Scholar]
  18. Lopez M., Zucker J. M., Urresola R., Douay L., Quintana E., Kemshead J., Gorin N. C., Vilcoq J. R. Influence of single and double immunomagnetic depletion on the hemopoietic capacity of marrow in patients with advanced neuroblastoma submitted to autologous bone marrow transplantation. Bone Marrow Transplant. 1987 Dec;2(4):413–419. [PubMed] [Google Scholar]
  19. Philip T., Bernard J. L., Zucker J. M., Pinkerton R., Lutz P., Bordigoni P., Plouvier E., Robert A., Carton R., Philippe N. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. J Clin Oncol. 1987 Feb;5(2):266–271. doi: 10.1200/JCO.1987.5.2.266. [DOI] [PubMed] [Google Scholar]
  20. Philip T., Gentet J. C., Carrie C., Farge A., Meziane F., Bouffet E., Zucker J. M., Kremens B., Brunat-Mentigny M. Phase II studies of combinations of drugs with high dose carboplatin in neuroblastoma (800 mg/m2 to 1 g 250/m2): a report from the LMCE group. Prog Clin Biol Res. 1988;271:573–582. [PubMed] [Google Scholar]
  21. Philip T., Ghalie R., Pinkerton R., Zucker J. M., Bernard J. L., Leverger G., Hartmann O. A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 1987 Jun;5(6):941–950. doi: 10.1200/JCO.1987.5.6.941. [DOI] [PubMed] [Google Scholar]
  22. Philip T., Helson L., Bernard J. L., Zucker J. M., Kremens B., Favrot M., Hartmann O. Definition of response and remission in children over one year of age with advanced neuroblastoma: proposition for a scoring system. Pediatr Hematol Oncol. 1987;4(1):25–31. doi: 10.3109/08880018709141246. [DOI] [PubMed] [Google Scholar]
  23. Philip T., Zucker J. M., Bernard J. L., Lutz P., Bordigoni P., Plouvier E., Robert A., Roché H., Souillet G., Bouffet E. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol. 1991 Jun;9(6):1037–1044. doi: 10.1200/JCO.1991.9.6.1037. [DOI] [PubMed] [Google Scholar]
  24. Pinkerton C. R., Philip T., Biron P., Frapazz D., Phillipe N., Zucker J. M., Bernard J. L., Philip I., Kemshead J., Favrot M. High-dose melphalan, vincristine, and total-body irradiation with autologous bone marrow transplantation in children with relapsed neuroblastoma: a phase II study. Med Pediatr Oncol. 1987;15(5):236–240. doi: 10.1002/mpo.2950150504. [DOI] [PubMed] [Google Scholar]
  25. Pinkerton C. R., Zucker J. M., Hartmann O., Pritchard J., Broadbent V., Morris-Jones P., Breatnach F., Craft A. E., Pearson A. D., Wallendszus K. R. Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group. Br J Cancer. 1990 Aug;62(2):319–323. doi: 10.1038/bjc.1990.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pole J. G., Casper J., Elfenbein G., Gee A., Gross S., Janssen W., Koch P., Marcus R., Pick T., Shuster J. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991 Jan;9(1):152–158. doi: 10.1200/JCO.1991.9.1.152. [DOI] [PubMed] [Google Scholar]
  27. Pritchard J., McElwain T. J., Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer. 1982 Jan;45(1):86–94. doi: 10.1038/bjc.1982.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rosen E. M., Cassady J. R., Frantz C. N., Kretschmar C., Levey R., Sallan S. E. Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience. J Clin Oncol. 1984 Jul;2(7):719–732. doi: 10.1200/JCO.1984.2.7.719. [DOI] [PubMed] [Google Scholar]
  29. Seeger R. C., Villablanca J. G., Matthay K. K., Harris R., Moss T. J., Feig S. A., Selch M., Ramsay N., Reynolds C. P. Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res. 1991;366:527–533. [PubMed] [Google Scholar]
  30. Shafford E. A., Rogers D. W., Pritchard J. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol. 1984 Jul;2(7):742–747. doi: 10.1200/JCO.1984.2.7.742. [DOI] [PubMed] [Google Scholar]
  31. Shuster J. J., Cantor A. B., McWilliams N., Pole J. G., Castleberry R. P., Marcus R., Pick T., Smith E. I., Hayes F. A. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol. 1991 Jun;9(6):1045–1049. doi: 10.1200/JCO.1991.9.6.1045. [DOI] [PubMed] [Google Scholar]
  32. Zucker J. M., Philip T., Bernard J. L., Michon J., Bouffet E., Gentet J. C., Lopez M., Coze C., Philip I., Bordigoni P. Single or double consolidation treatment according to remission status after initial therapy in metastatic neuroblastoma: first results of LMCE 3 study in 40 patients. Prog Clin Biol Res. 1991;366:543–551. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES